MedTrace Logo

Usability and Tolerability of the Norditropin NordiFlex® Injection Device in Children Never Previously Treated With Growth Hormone

NCT01327924 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 77

Last updated 2014-06-24

No results posted yet for this study

Summary

This study is conducted in Europe. The purpose of this study is to assess the impact on daily life for children new to using a growth hormone injection device.

Conditions

  • Growth Hormone Disorder
  • Growth Hormone Deficiency in Children
  • Genetic Disorder
  • Turner Syndrome
  • Foetal Growth Problem
  • Small for Gestational Age
  • Chronic Kidney Disease
  • Chronic Renal Insufficiency
  • Delivery Systems

Interventions

DRUG

Norditropin NordiFlex®

Daily administration by subcutaneous injection (under the skin). Starting dose and frequency will be determined by the physician as part of normal clinical practice.

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Registry (GCR, 1452) · Novo Nordisk A/S

Eligibility

Max Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-04-30
Primary Completion
2012-06-30
Completion
2012-06-30

Countries

  • France

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01327924 on ClinicalTrials.gov